{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:05:23Z","timestamp":1779743123800,"version":"3.53.1"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Study Design.<\/jats:title>\n                    <jats:p>A break-even cost-effective analysis<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To evaluate the cost-effectiveness of recombinant human bone morphogenetic protein\u20132 (rh-BMP-2) for preventing symptomatic pseudarthrosis requiring revision surgery in posterolateral lumbar fusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of Background Data.<\/jats:title>\n                    <jats:p>Spinal fusion rates differ across surgical techniques and are influenced by approach, graft selection, and patient factors. Although rh-BMP-2 has been shown to improve fusion rates, its widespread use remains limited by high upfront costs and uncertainty regarding cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>A break-even analysis framework was used to determine the absolute risk reduction (ARR) in symptomatic pseudarthrosis required for rh-BMP-2 to be cost-effective. Model inputs were derived from published literature and included low (2%) and high (15%) baseline symptomatic pseudarthrosis rates requiring revision surgery, rh-BMP-2 costs before and after surgeon cost awareness, and two-year costs of treating pseudarthrosis using combined direct and indirect cost models. Base-case and one-way sensitivity analyses were performed to assess the impact of baseline pseudarthrosis risk, rh-BMP-2 cost, revision surgery cost, and surgeon cost awareness, defined as adjusting rhBMP-2 dosages to reduce surgical costs. Break-even number needed to treat (NNT) values were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Rh-BMP-2 was cost-effective only at high baseline symptomatic pseudarthrosis rates across both cost models. Using surgical-only revision costs, rh-BMP-2 was cost-effective at high baseline pseudarthrosis rates with an ARR of 14.32% (NNT = 7) prior to surgeon cost awareness and 7.89% (NNT = 13) after cost awareness. At low baseline pseudarthrosis rates, rh-BMP-2 was not cost-effective regardless of product cost. Sensitivity analyses demonstrated that surgeon cost awareness and higher revision costs expanded scenarios in which rh-BMP-2 was cost-effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Rh-BMP-2 is most likely to be cost-effective in posterolateral lumbar fusion among patients with a high baseline risk of pseudarthrosis, particularly with substantial revision costs and surgeon cost awareness. These findings support a selective, risk-stratified approach to rh-BMP-2 utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence.<\/jats:title>\n                    <jats:p>III<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/brs.0000000000005745","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:00:09Z","timestamp":1779742809000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) to Prevent Symptomatic Pseudarthrosis in Posterolateral Lumbar Fusion"],"prefix":"10.1097","author":[{"given":"Brandon J.","family":"Martinazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-055X","authenticated-orcid":false,"given":"Mitchell","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Toci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler W.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Giakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Hitchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Eichbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Canseco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Hilibrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Rihn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Kepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,14]]},"container-title":["Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BRS.0000000000005745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:00:10Z","timestamp":1779742810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BRS.0000000000005745"}},"subtitle":["A Break-Even Cost-Effective Analysis"],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/brs.0000000000005745","relation":{},"ISSN":["0362-2436","1528-1159"],"issn-type":[{"value":"0362-2436","type":"print"},{"value":"1528-1159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"2026-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}